Merck antifungal licensed
The FDA has approved Merck & Co's caspofungin acetate (Cancidas) to treat invasive aspergillosis in patients who do not respond to or cannot tolerate other antifungal therapies. The drug is the first in a new class, glucan synthesis inhibitors.